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Photopheresis, the process by which peripheral blood is exposed in an extracorporeal flow
system to photoactivated 8-methoxypsoralen (8-MOP), is a new treatment for disorders caused
by aberrant T lymphocytes. It is now a standard therapy for advanced cutaneous T-cell
lymphoma and shows promise in the treatment oftwoautoimmune disorders, pemphigus vulgaris
and progressive systemic sclerosis (scleroderma). Additional diseases for which clinical trials are
in progress include multiple sclerosis, organ transplant rejection, rheumatoid arthritis, and AIDS.
The mechanism of action appears to involve a "vaccination" against the pathogenic T cells, in a
clone-specific manner. Photoactivated 8-MOP initiates a cascade of immunologic events by
forming covalent photoadducts with nuclear and cell surface-adherent DNA and possibly with
other cellular molecules. For reasons not yet fully clarified, but probably related to enhanced
cycling of the T-cell receptor for antigen, photopheresis increases the immunogenicity of the
irradiated T cells so that their reinfusion induces a therapeutically significant immunologic
reaction that targets unirradiated Tcells ofthe pathogenic clone(s). Thespecificity ofthe induced
immunologic reaction probably results from the extremely disproportionate expansion of the
pathogenic clone(s), relative to the several million other clones ofnormal T cells.
This special issue of The Yale Journal ofBiology and Medicine is devoted to an
in-depth analysis of the clinical potential and scientific basis of photopheresis, an
exciting new approach to the treatment ofdisorders, neoplastic or autoreactive, caused
by aberrant T lymphocytes. Evidence has been rapidly accumulating, indicating that
the human immune system, even when inundated by very large numbers of disease-
provoking T cells, can be immunized against these cells by photopheresis in such a way
that otherwise progressive disorders can be suppressed and even controlled. By
bringing this body of work together for the first time under a single cover, we have
attempted to tell the story in a cohesive manner, which will help stimulate others to
contemplate, to investigate, and to implement the concept that clinicians may be able
to harness the power ofthe immune system to control serious diseases.
Photopheresis, which is now approved by the Food and Drug Administration (FDA)
for the treatment ofcutaneous T-cell lymphoma (mycosis fungoides, Sezary syndrome,
and related presentations), is showing substantial promise in a variety ofautoimmune
disorders and is operative in over 40 centers in the United States and abroad (Table 1).
Therefore, it is appropriate to review its status and to highlight several relevant
practical issues. This article will serve as a clinical update and will summarize our
growing knowledge as to how photopheresis works.
First, it would be helpful to discuss briefly the origin of the concept that diseases
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TABLE 1
Photopheresis Centers
University of Pennsylvania
Philadelphia, Pennsylvania
University ofCalifornia
San Francisco, California
Medical College ofWisconsin
Milwaukee, Wisconsin
Boston University
Boston, Massachusetts
University ofTexas
Dallas, Texas
M.D. Anderson
Houston, Texas
Kenneth Norris Cancer Center
Los Angeles, California
University ofSouthern California
Los Angeles, California
Wishard Memorial
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
Washington Hospital Center
Washington, D.C.
University ofNebraska
Omaha, Nebraska
Columbia University
New York, New York
Georgetown University
Washington, D.C.
Cleveland Clinic
Cleveland, Ohio
Cedar Sinai Hospital
Miami, Florida
University ofSouth Carolina
Charleston, South Carolina
Mt. Sinai Hospital, Miami
Miami, Florida
Civitan Blood Center
Gainesville, Florida
Oklahoma Blood Center
Oklahoma City, Oklahoma
Loyola University Hospital
Maywood, Illinois
University ofUtah
Salt Lake City, Utah
Polyclinic Hospital
Harrisburg, Pennsylvania
University of Minnesota
Minneapolis, Minnesota
University of Dusseldorf
Dusseldorf, West Germany
National Cancer Institute, Japan
10 participating centers
Aachen Hospital
Aachen, West Germany
U.S.A.
Yale University
New Haven, Connecticut
University ofPittsburgh
Pittsburgh, Pennsylvania
Henry Ford Hospital
Detroit, Michigan
University of Michigan
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Scripps Clinic
La Jolla, California
Mount Sinai Medical Center
New York, New York
Ochsner Foundation
New Orleans, Louisiana
Duke University
Durham, North Carolina
Vanderbilt University/VA Medical
Center
Nashville, Tennessee
Morristown Hospital
Morristown, New Jersey
New York University/VA Medical Center
New York, New York
Thomas Jefferson University
Philadelphia, Pennsylvania
Hahnemann University
Philadelphia, Pennsylvania
University ofCleveland
Cleveland, Ohio
Tulane University
New Orleans, Louisiana
University ofAlabama
Birmingham, Alabama
Southwest Florida Blood Center
Tampa, Florida
Good Samaritan Hospital
Los Angeles, California
Harper Hospital
Detroit, Michigan
Northwestern University
Chicago, Illinois
Puget Sound Blood Center
Seattle, Washington
Grandview Hospital
Dayton, Ohio
Europe andAsia
University ofVienna
Vienna, Austria
Hospital Avicenne
Paris, France
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caused by expanded populations of pathogenic T cells can be effectively treated by
extracorporeal photochemotherapy. This procedure evolved from an awareness that
current approaches to the treatment of disorders of the immune system are quite
nonspecific and toxic. The normal human body selectively regulates the expansion and
suppression ofeach ofthe several million distinct clones ofT cells which form the core
ofthe immune system, permitting the rapid mobilization ofthose T cells necessary for
anti-microbial defenses but inhibiting the activity of the same cells when their efforts
are no longer required. In comparison, our most commonly applied tools for treatment
of disorders of the lymphocyte or immune system are extremely crude. Systemic
corticosteroids, antimetabolites, and cyclosporine A do not discriminate between
individual clones of pathogenic and benign T cells and lead to many documented side
effects. Bioengineered molecules, such as monoclonal antibodies and cytokines, will
certainly find niches in our therapeutic armamentarium but are nonspecific and affect
many types oftarget cells. Therefore, noneofthese therapeutic agents approximate the
efficiency with which the normal body deals with its own T cells.
MECHANISM UNDERLYING RESPONSE TO PHOTOPHERESIS
A far more desirable approach would be the development of a means of dealing
directly with the clones of T cells which actually cause a disease, while sparing the
innocent clones. Studies in experimental animals, largely conducted by Irun Cohen and
his colleagues at the Weizmann Institute in Israel over the past decade, have suggested
that this goal may well be attainable [1,2]. Those investigators found that physically
altered pathogenic T cells can be presented to an animal in such a manner that, instead
of causing disease, they actually vaccinate against the development of the illness. The
experimental system which the investigators used most extensively is experimental
autoimmune encephalomyelitis (EAE).
EAE can be induced in rats by immunizing them with basic myelin protein extracted
from the central nervous system of guinea pigs and presented to the rat in complete
Freund's adjuvant, a preparation which markedly enhances efficiency ofimmunization
[3]. Virtually all ofthese rats develop an acute paralytic syndrome, which is frequently
fatal and which is associated with a T-cell infiltration of the central nervous system.
That the disease is actually caused by T cells which specifically react against basic
myelin protein has been demonstrated by the extraction from affected rats of such T
cells, clonal expansion of these cells in vitro, and intravenous introduction of these
anti-basic myelin protein T cells into healthy rats. The recipients of these anti-basic
myelin protein T cells then develop a florid EAE, even though they themselves were not
immunized with basic myelin protein.
Cohen's group then made the startling observation that resistance to the subsequent
development of EAE could be induced by first vaccinating potential recipients against
the otherwise pathogenic anti-basic myelin protein T cells. This work was accom-
plished by initially treating the pathogenic cloned T cells in ways (glutaraldehyde,
hydrostatic pressure) that made their cell membranes more rigid and more efficiently
exposed cell surface antigens that distinguished the anti-basic myelin protein T cells
from all other T cells. Their data indicated that the most likely T-cell surface
structures leading to the observed effects were the T-cell receptors (TCR) for specific
foreign antigen. T cells react with foreign antigens in a manner analogous to the way
that antibodies bind to appropriate ligands. T cells accomplish this process via
membrane receptors, unique to each clone of T cells, capable of binding appropriately
presented foreign antigens. Each T-cell clone bears a unique receptor, composed of two
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disulfide-linked protein chains with distinctive amino acid sequences [4]. It is the
three-dimensional structure of these receptors that confers specific binding properties
and permits each of the several million clones of T cells to operate independently.
One of the ways that the normal individual regulates the proliferation of individual
clones of T cells is tosingle out the T cells on the basis ofthe T-cell receptor for antigen:
antibodies and cellular responses are produced which selectively target the appropriate
T-cell clone(s)'s T-cell receptor. Since the TCR of each clone has its own distinct
amino acid sequence, it is also uniquely antigenic. It appeared that Cohen's team had
discovered several ways to make the anti-basic myelin protein T-cell receptor
sufficiently antigenic so that, when the treated cells were infused into rats, the animals
developed such a strongclone-specific immunologic response that subsequently infused
living pathogenic T cells of the same clone were either destroyed or inhibited. When
these animals were appropriately prepared, it was not possible to induce in them florid
EAE. Since it was still possible to induce in them other autoimmune disease by infusion
of unrelated clones of T cells, it was clear that the effect was truly clone-specific.
Those studies were ofcritical importance and clearly demonstrated that it is possible
to vaccinate against the activity of pathogenic clones of T cells. Three major hurdles
existed, however, before it would be possible to consider extending these observations
to the treatment of humans with diseases caused by expanded clones of malignant or
autoreactive T cells. First, the methods employed by Cohen's group (glutaraldehyde,
hydrostatic pressure) were not readily applicable to reinfusable human blood. Second,
patients always present with disease, not prior to developing illness. Hence, it would
ultimately need to be demonstrated that vaccination against T-cell activity could be
effective even in the face ofprogressive disease, rather than prophylactically as in the
ratsystem. Finally, invirtually all autoimmune diseases and even in most patients with
cutaneous T-cell lymphoma, it is not possible accurately to identify or isolate the
pathogenic clone(s). Therefore, the only plausible way to proceed was to deal with the
intactpatient's whole blood andhope that the pathogenic clone(s) would be sufficiently
expanded compared to all other individual clones ofnormal T cells that in vitro cloning
would not be required. As we will see, solutions to each of these challenges were
forthcoming.
The impractical glutaraldehyde and hydrostatic pressure approaches were effec-
tively replaced by use of ultraviolet A (UVA)-activated 8-methoxypsoralen (8-MOP).
Several features distinguish psoralens from nearly all other clinically useful drugs
[5,6]. First, in the absence oflight they are extremely safe and, in fact, without known
biologic function. Second, once activated by ultraviolet energy, they exhibit an
exceptional ability to bind covalently to target molecules in a manner which severely
interrupts cellular function. Third, the type of ultraviolet energy, ultraviolet A, which
photoactivates psoralen compounds, iscapable ofpassing through clear plate glass and
certain plastics and is of lower energy than ultraviolet B, which causes sunburn and
generally does not pass through those materials. Fourth, once photoactivated, the
transiently energized psoralen remains active for microseconds (millionths of a
second), an interval longenough to bechemically reactive and short enough so that, for
practical purposes, once the light source is turned off, unbound psoralen reverts to its
inert form. In essence, psoralens provide the clinician with drugs of high chemothera-
peutic potency, butonly where and when thepsoralens come in contact with light of the
appropriate wavelength. Compounds of this family, therefore, offer a completely
directed form of chemotherapy.
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In the early 1950s, a group of investigators led by Aaron B. Lerner and Thomas B.
Fitzpatrick at the University of Michigan demonstrated that a concentrated oral form
of 8-MOP had a high margin ofsafety: the ratio ofthe maximal safe concentration of
the drug to that required for clinical effect [7]. Studies with this purified form of
8-MOP substantiated the earlier clinical findings ofEl Mofty in Egypt that its oral use
in conjunction with exposure of the skin to sunlight improved many patients with
vitiligo, by stimulating their residual melanocytes. In the early 1970s, John Voorhees
and his colleagues, also at the University of Michigan, found that topically applied
psoralen followed by sunlight improved some patients with psoriasis [8]. Psoriatic
epidermal cells actually divide more rapidly than do cells of most cancers but are not
malignant, since they do not invade other tissues and can be returned to normal
behavior patterns by effective therapy. In the late 1970s, John Parrish and his
colleagues at Harvard, including Madhu Pathak and Fitzpatrick, led a multi-
institutional group which found that orally administered 8-MOP followed by total skin
exposure to high-intensity UVA was largely effective in clearing extensive psoriatic
lesions which had otherwise been quite resistant to other treatments [9].
During that same period oftime, Barbara Gilchrest and her co-workers at Harvard
found that localized skin lesions of cutaneous T-cell lymphoma (CTCL) resolved in
response to the same regimen [10]. CTCL is the most common adult malignancy ofT
lymphocytes and typically has an initial phase characterized by skin lesions containing
large numbers of the malignant cells [11]. These clinical observations highlighted a
series of laboratory studies, which had been proceeding in my laboratory (which was
then at Columbia University), in Kenneth Kraemer's at the National Institutes of
Health, and in Warwick Morrison's at Harvard, which all revealed that human T
lymphocytes were quite sensitive to the combined effects of8-MOP and UVA [12,13].
Furthermore, it had long been known that up to 25 percent of the blood supply passes
through blood vessels of the skin and that UVA is capable of penetrating the full
thickness ofthe skin, in attenuated amounts. Therefore, large numbers ofcirculating T
cells must have been exposed to both UVA and 8-MOP during psoriasis treatments,
and yet serious systemicsequelae to the immune system had not been reported. In fact,
although approximately 2 percent of psoriatic patients treated repetitively with UVA
and 8-MOP developed low-grade skin cancers, no increased numbers of patients with
malignancies of white blood cells or increased susceptibility to infection were recog-
nized among the thousands ofsubjects followed prospectively.
Paul Khavari from our group at Yale, working in close association with Cohen's
group at the Weizmann Institute, found that exposure of the EAE-causing T-cell
clones to 8-MOP/UVA wasactually moreeffective than glutaraldehyde or hydrostatic
pressure in leading to a beneficial vaccination effect in rats [14]. This finding was very
exciting, because it suggested that extracorporeally routed human blood could be
exposed to photoactivated 8-MOP and safely returned to the patient without introduc-
tion ofsignificant systemic toxicity or generalized immunosuppression. Although there
are clearly several ways to induce the vaccination against T cells, it was noteworthy
that 8-MOP/UVA treatment of the cells was most effective and safest. Khavari also
produced preliminary evidence that cell membranes isolated from 8-MOP/UVA-
treated T cells could be used to vaccinate, indicating that the treatment had led to an
effect in the T-cell membrane, in addition to the known effects of 8-MOP on nuclear
DNA.
Carole Berger, Maritza Perez, and Liliane Laroche at Columbia and Yale Universi-
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ties made several major observations in other experimental systems that were then
developed to a greater degree and arediscussed in detail elsewhere in this issue [15,16].
They found that the systemic lupus erythematosus-like disease which spontaneously
develops in the inbred strain of MRL mice could be prevented or slowed by vaccinating
young mice of that strain, prior to development of disease, with unfractionated
8-MOP/UVA-treated spleen lymphocytes from old diseased mice. These mice are
clinically and serologically normal at birth but by young adulthood develop markedly
elevated anti-native DNA antibodies, renal disease, splenomegaly, and massive
lymphadenopathy. Berger and associates found that vaccination of young mice with
8-MOP/UVA-treated cells from diseased adults prevented development of the anti-
DNA antibodies, greatly decreased splenomegaly and lymphadenopathy, and signifi-
cantly prolonged survival times. Similarly, rejection ofskin transplants from unrelated
mice could be greatly impeded by vaccinating potential recipients with unfractionated
8-MOP/UVA-treated splenocytes from animals undergoing rejection of genetically
identical skin grafts, and an immunologic response to a foreign antigen could be
prevented by vaccination with unfractionated splenocytes from animals already
manifesting the immunologic response against the same antigen. The power of this
approach to control of the pathogenic clones was indicated by the capacity of this
"T-cell vaccination" to occur in the absence ofany other manipulation of the immune
system. The extreme specificity of the approach was revealed by the clone-specific
nature ofthe vaccination: the clones used in the photoinactivation and reinfusion steps
induced immunity only against themselves and not against irrelevant T-cell clones.
The major significance of these observations was that one could vaccinate against a
particular T-cell activity without actually isolating or even identifying the clone(s)
responsiblefor the activity. The splenocyte populations in each ofthe above-described
experimental systems contained markedly expanded clones of T cells capable of
causing the lupus-like syndrome, mediating rejection of a particular skin graft, or
reacting to a certain foreign antigen. It appeared that even though these expanded
T-cell clones were admixed with many smaller irrelevant clones, the body was able
selectively to react immunologically only against the expanded clones. That is,
sufficient numbers of photoinactivated effector T or "PET" cells had been altered to
lead to an immunologic reaction against them after their infusion, while the small
numbers of T cells in each of the multitude of irrelevant clones came in "under the
radar" of the immune system. That finding indicated that it should be possible to
accomplish the same end by extracorporeally exposing human blood, containing
expanded populations of disease-provoking T cells mixed with a multitude of much
smaller clones of passenger normal T cells, to 8-MOP/UVA and then returning the
photodamaged white blood cell mix to the patient.
CLINICAL TRIAL
The highly refined apparatus necessary to perform this extracorporeal procedure,
known now as "photopheresis," was developed by engineers at Therakos, Inc., a
subsidiary ofJohnson and Johnson, Inc. The equipment combines an initial centrifuga-
tion step to enrich for lymphocytes with an elaborate ultraviolet exposure system, with
all phases controlled by microprocessors and multiple monitors.
Several preliminary steps were required prior to beginning a clinical trial of
photopheresis. First, we needed to determine the optimal conditions for the procedure.
Because psoriasis patients readily tolerated blood levels of 50 to 200 nanograms of
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8-MOP per milliliter ofblood [9], we chose to administer the drug orally in exactly the
same dosage as they received. Since we found that cell division by T cells could be
almost completely blocked by I to 2joules per square centimeter ofUVA energy in the
presence of 100 nanograms per milliliter of8-MOP, we chose to expose the blood cells
to this amount of energy. The weakness of the UVA energy, an advantage in
minimizing undesirable side effects on other blood components, required an extremely
thin blood film in the exposure system: in the currently used third-generation
apparatus, blood is passed at a film thickness of only I millimeter between two
high-intensity UVA energy sources, translating to a maximal distance between the
targetted T cells and the light ofonly 0.5 millimeters. The total volume ofpatient blood
outside the body during the treatment is approximately one unit or 500 milliliters, the
same volume which an individual typically donates to a blood bank. To titrate the
amount of UVA "seen" by the average T cell passing through the system to that which
we had previously determined to be optimal for T-cell inactivation, Francis P.
Gasparro and Regina Santella of our group produced monoclonal antibodies which
recognized 8-MOP-DNA photoadducts in irradiated cells and permitted their quantif-
ication [17]. From predetermined dose-response curves, we were able todetermine that
150 minutes of UVA exposure in the photopheresis apparatus were necessary to reach
our goal ofclose to 2joules per square centimeter of irradiation.
In order to justify using such an experimental modality, the first group of patients
treated with this approach needed to fulfill certain requirements. They had to have
an extremely debilitating and dangerous disease, unresponsive to standard therapy,
caused by circulating T lymphocytes. The disease which we selected, the leukemic
variant of cutaneous T-cell lymphoma (CTCL), is characterized by massive expansion
of a malignant clone of helper T cells. Those malignant T cells migrate between the
skin, which they infiltrate in such a manner that the total surface of that organ is red
and swollen, and other body tissues via the blood and lymphatic vessels [11]. This
phase of CTCL not only completely debilitates the victim but is associated with a
median expected survival, when treated by standard means, of less than three years,
with patients succumbing to opportunistic infections or destruction of vital organs by
the malignant cells, as revealed by a recent multi-center prospective clinical study
[18].
We began treating patients with a conservative regimen: photopheresis on two
successive days at monthly intervals, a protocol initially intended merely to establish
the toxicity ofthe new procedure. We realized that such a low frequency oftreatments
would permit irradiation of less than 10 percent of the total body burden of malignant
cells, since so many of them were harbored in the skin and lymphoid tissues, and
anticipated that, once the safety of the procedure was established, we would need to
increase the frequency oftreatments substantially. It therefore astounded us to see that
four of the first five patients responded after only six to ten treatments and that
eventually the severely involved skin of two of these patients cleared completely. This
exceptional level of response, not noted with far more intensive cell removal by simple
leukapheresis, indicated that, as the experimental studies in rodents suggested, the
body's immunologic response to the reinfused UVA-irradiated T cells was leading to a
profound clinical response.
A multi-institutional study was organized, with advice from the Food and Drug
Administration, to expand the numbers of patients [19]. At the medical centers of
Columbia University, University of Pennsylvania, University of California in San
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Francisco, University of Pittsburgh, Yale University, University of Vienna, and
University of Dusseldorf, a total of 37 patients with CTCL unresponsive to standard
therapy were treated and 27 responded, including nine with complete or nearly
complete clearing of the skin infiltration. Responders included 20 of 26 subjects
presenting with lymph node involvement. This level of clinical response in a disorder
otherwise known to be extremely resistant to conventional chemotherapy was notewor-
thy. Several additional features of the study were also remarkable. As compared to
standard chemotherapy, the systemic side effects were minimal and in no instance
prevented continuation of the treatments. Approximately 10 percent of the patients
had a fever following the reinfusion of the damaged cells, but this febrile response
completely resolved within 24 hours. Other problems, associated with leukapheresis
(increased susceptibility to infection and depletion of other blood elements) or with
standard chemotherapy of CTCL (bone marrow suppression, hair loss, intestinal
bleeding from erosions, severe nausea), were not experienced. Nevertheless, the
follow-up period has been too short to permit recognition oflong-term side effects, and
it remains possible that idiosyncratic adverse reactions will be recognized as larger
groups of patients are treated now that the procedure has received approval from the
FDA for management of advanced CTCL. Elsewhere in this issue, Peter Heald has
updated the now extensive experience at the Yale-New Haven Medical Center with
photopheresis treatment ofCTCL patients.
RECOMMENDATIONS FOR USE OF PHOTOPHERESIS IN CTCL
Since that clinical trial was completed four years ago, additional clinical experience
with those and other CTCL patients led to the following conclusions and recommenda-
tions.
Cutaneous T-Cell Lymphoma (CTCL) Patient Selection
Our longest clinical experience has been with the erythrodermic variant of CTCL,
since 27 patients in the original clinical trial were in this category. The best responders
were individuals who were immunocompetent, as described below, so that they were
apparently able to mount an immunologic response to the reinfused photodamaged
pathogenic lymphocytes. Patients who were not immunocompetent sometimes
responded significantly, if they were treated frequently (up to twice weekly). This
response by the immunoincompetent patients results from simple physical destruction
of the malignant cells in the absence of an immunologic reaction against them; this
type of response tends to be relatively short-lived, and the frequent treatments
necessary to maintain it are impractical. Therefore, we recommend limitation of the
therapy to the immunocompetent group.
More recently, we and others have begun to include patients with cutaneous tumors
or extensive plaques in the absence ofidentifiable visceral tumors. It seems quite likely
that such patients have hematogenous spread, given the known high recurrence rate of
skin lesions following clearing induced by total body electron beam radiotherapy.
Although the initial results have been variable, several of these patients appear to be
maintaining remission following total body electron beam irradiation coupled with
monthly photopheresis.
In this group ofpatients with tumors or extensive plaques, we are attempting to use
photopheresis to maintain post-beam remissions. This group, in fact, now constitutes
the largest new population whom we are treating. We have chosen to use photopheresis
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for these patients, since the chemotherapeutic alternatives have limited efficacy and
major attendant side effects. Prospective analysis of the results obtained in this
population of patients by the cumulative photopheresis treatment group will determine
whether the optimism generated by our preliminary observations in extensive plaque
and tumor patients (treated by beam plus photopheresis) can be sustained.
Patients with plaque stage disease involving less than 15 percent of the body surface
and lacking identifiable abnormal circulating cells are treated by us with either
electron beam, PUVA, or nitrogen mustard, since those therapies can be rather
effective in controlling the disease. Patients with plaque stage CTCL involving more
than 15 percent of the body, with or without recognizable abnormal circulating T cells,
as well as patients with more limited skin involvement but with readily demonstrable
blood involvement, are treated by us with electron beam followed by photopheresis. We
reiterate that, while we are encouraged by the preliminary results, it is too early to
assess the efficacy of this combination of modalities formally.
Patient Evaluation
In addition to obtaining baseline abdominal CAT scans (to identify retroperitoneal
nodes, splenic or hepatic involvement, and so on), chest X-rays (to identify hilar
adenopathy or diffuse parenchymal infiltration), and routine blood profiles, cardio-
grams, and urinalyses, two specialized determinations of immunocompetence have
been particularly helpful. Blood T-cell subsets should be analyzed using commercially
available (Ortho, Becton-Dickinson, Coulter) monoclonal antibodies to determine both
absolute and relative numbers of phenotypically abnormal cells. An indication of
probable immunocompetence can be obtained from an estimation of the residual
phenotypically normal helper/inducer and suppressor/cytotoxic T-cell subsets. For
example, if the majority of the OKT3-positive T cells lack either OKTI or OKT4
positivity, it can be assumed that few residual normal helper T cells persist and that the
individual may be immunocompromised. Reactivity with the monoclonal antibody
BE2, a marker of the malignant state, should be performed with a cytofluorograph.
BE2 antigen is expressed in low quantity by many malignant T cells, and appropriate
adjustment of the gains, as shown by Peter Heald at Yale, on the cytofluorograph
will be required to recognize its presence. If this BE2 determination is accurately
performed, the level of positive cells can be assessed longitudinally to help monitor
response to therapy. It is noteworthy that Heald and Berger have shown that BE2 is
actually an activation antigen, aberrantly expressed by CTCL cells. A phytohemag-
glutinin (PHA) stimulation assay of peripheral blood lymphocytes appears to be
sufficient to distinguish many of the immunocompetent patients from the immunoin-
competent ones. It is our recommendation to preclude those individuals with a greater
than 50 percent diminution of PHA responsiveness from the treatment program.
Adjunctive Therapies
As indicated above, we routinely treat cutaneous tumors with radiotherapy and then
introduce photopheresis. We have also been impressed with long-term responses of
several patients who have received radiotherapy to markedly enlarged peripheral
lymph nodes which were present before photopheresis or which developed during the
course of treatment. It is our impression that simultaneous daily administration
of immunosuppressive medications, particularly corticosteroids, should be avoided
because of the preclusion of immunologic response to reinfused cells. Instead, we have
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been quite impressed with efficacy of weekly oral methotrexate given as a single dose,
ranging from 15 to 25 mg. Several partial responders to photopheresis improved
greatly with addition of the methotrexate over two or more months.
Frequency ofTreatment
During the clinical trial and in our subsequent experience, we found that some
patients were particularly resistant to the effects of photopheresis. Some of these
patients may benefit from increasing the frequency oftreatment to every two weeks. In
these individuals, when the response is maximal, treatment frequency may be de-
creased to every four or five weeks. Some patients who are less immunocompetent may
then experience renewed disease progression with return to lower treatment frequency.
The transient improvement which they experience while being treated more frequently
is probably a reflection of physical destruction ofthe malignant cells in the absence of
an immunologic response against them.
Length ofTreatment Course
Whereas a number of erythrodermic CTCL patients have responded quite impres-
sively within three months, most require significantly longer treatment periods. The
majority of patients during the clinical trial required six months to demonstrate a 25
percent improvement. In addition, the majority ofpatients reach a maximal plateau of
response, if less than complete, in six to eighteen months.
Weaning OffPhotopheresis
With the exception of the rare individual who responds completely and can be
maintained in remission completely off photopheresis, most patients require a gradual
diminution of treatment frequency to determine the minimal acceptable intensity of
the treatment program. We tend to stretch the intervals between treatments progres-
sively to six weeks, to eight weeks, and occasionally to longer periods, while closely
monitoring the clinical course. Because of the limited total experience with this
approach, it is too early to make definitive recommendations.
Survival Data
The information on the survival of the 27 erythrodermic CTCL patients from the
clinical trial is encouraging. The majority of the patients (67 percent) are still alive,
with a median survival time from the diagnosis of erythrodermic CTCL of 43.5
months. This time span is in excess of the anticipated 30 months reported by the
National Mycosis Fungoides Study Group in the Annals ofInternal Medicine. Since
most ofthe patients are still alive, the data are certain to become even more impressive
with time.
While several of the complete responses have been remarkable and some have been
maintained off therapy for more than four years, it is not surprising that the
established malignancy in other patients can be difficult or impossible to eradicate
by an immunologic reaction against the malignant cells. Yet one must be encouraged
by the apparent capacity of continually administered photopheresis to slow the
progression of the disease in a majority ofthe incomplete responders.
From this extensive experience with CTCL, we may now have important leads as to
how to apply these principles to the treatment ofa wide spectrum ofdiseases caused by
lymphocytes: from lymphocytic leukemias to autoimmune disorders, such as rheuma-
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toid arthritis and lupus, and even potentially to organ rejection. Current clinical trials
include treatment of patients with rapidly progressive systemic sclerosis, rheumatoid
arthritis, multiple sclerosis, chronic lymphocytic leukemia, pemphigus vulgaris, and
rejection of transplanted organs. The majority of the treatment centers are in
departments of dermatology, even though several of the diseases in the clinical trials
are non-dermatologic. In general, dermatology groups are fully managing those
individuals with major cutaneous components to their disorder, while merely supervis-
ing the photopheresis procedure in management of non-dermatologic patients. This
latter situation is analogous to that of the radiotherapist's relationship to the referring
oncologist. Clearly, however, the jurisdiction over the procedure will vary from center
to center, particularly as those in other medical specialties become increasingly aware
of photopheresis.
FUTURE PHOTOACTIVATABLE DRUGS
But is 8-MOP, a naturally occurring plant product, the ideal chemical agent for
photopheresis? Whereas it has the advantage over some other naturally occurring
psoralens, such as angelicin, of being able to form bifunctional adducts and therefore
DNA cross-links, its absorption from the intestinal tract is highly variable and
unpredictable. For example, in the same patient, under apparently identical conditions,
Gasparro and associates have shown that blood levels may vary by more than 200
percent on different days. Clearly then, a simple advance will be the development of a
solution of known concentration which could then be administered directly into the
flow system of photopheresis. Blood levels, currently obtained after oral administration
of8-MOP, are in the range of 100 nanograms per milliliter or 500 micrograms per total
five-liter blood volume of the average adult. If to 500 ml of extracorporeal blood only
50 micrograms of 8-MOP were added, one would obtain a more predictable 100-
nanogram concentration per milliliter in UVA-irradiated blood, which would quickly
be diluted to only one-tenth that level on return of the blood to the patient. One could
actually add ten times that amount to the blood and potentially shorten the irradiation
period greatly.
A second simple forward step would be to replace 8-MOP with its synthetic
analogue, amino-methyl-trimethylpsoralen (AMT) [20], which has far greater water
solubility as well as affinity for DNA, leading to, as shown by Gasparro, Berger, and
colleagues, much greater activity per molecule. More efficient formation of monoad-
ducts with DNA and then conversion of the monoadducts to bifunctional adducts or
DNA cross-linkers is also possible by re-engineering of the lights, since Gasparro and
associates have shown that the DNA cross-link occurs most efficiently at 340 nM of
UVA [21]. In short, it should be possible in the near future to refine the procedure
substantially.
It may also become desirable to deliver the photoactivatable drugs more selectively
to appropriate target cells in extracorporeally routed blood. We have obtained
laboratory evidence that this process could be accomplished in several ways. For
example, by placing monoclonal antibodies on the surface of lipid vesicles, liposomes,
which contain the photoactive molecule pyrene, Yemul and colleagues [22] have been
able to cause these vesicles to bind selectively to target cells against which the
monoclonal antibodies are directed. Subsequently delivered UVA leads to destruction
of only the cells to which the liposomes had bound. Whereas liposomes delivered
intravenously are rapidly filtered out of the bloodstream by the liver and spleen, they
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might be more effectively used in the extracorporeal system of photopheresis where
they would be directly mixed with the target white blood cells.
CONCLUSIONS
Photopheresis is an exciting new therapeutic approach to the management of
diseases caused by abnormal circulating lymphocytes. Whereas it is already approved
by the FDA for management ofextensive cutaneous T-cell lymphoma, its applicability
in the treatment ofa broad spectrum ofautoimmune diseases will be determined from
the results of additional clinical trials. Elsewhere in this issue, preliminary clinical or
research findings are presented, suggesting that photopheresis may have a place in the
treatment of such diversified immunologic disorders as scleroderma, rheumatoid
arthritis, multiple sclerosis, pemphigus vulgaris, and heart transplant rejection. The
mechanism of action appears to be, at least in large part, an autovaccination against
pathogenic clone(s) of T cells. The exciting possibility, therefore, exists that the
importance of this new therapeutic modality may substantially increase in the next
decade.
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